抗逆转录病毒治疗与HIV感染女性CIN管理后随访中高级别宫颈上皮内瘤变(CIN2+)检测的系统综述与荟萃分析
该系统综述与荟萃分析检索了1996年至2020年的文献,纳入8项研究共1452名HIV感染女性,评估抗逆转录病毒治疗(ART)、CD4+计数和HIV血浆病毒载量(PVL)与CIN管理后随访中组织学确诊CIN2+检测的关联。结论支持早期ART及将CIN2+筛查和管理整合入HIV关怀。
要点
- ART可能降低HIV感染女性CIN管理后随访中CIN2+检出风险,高收入国家显著。
- HIV PVL<50 copies/ml与CIN2+检出风险降低相关(cOR=0.55)。
- 基线CD4+≥350 cells/µl者CIN2+检出风险显著降低(aHR=0.35)。
核心结论
- ART可能降低CIN管理后随访中CIN2+检出风险,充分HIV控制联合切除性CIN治疗可能增强此效应。
- 研究结果支持早期ART及将CIN2+筛查和管理整合入HIV关怀的建议。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、Global Health和PubMed从1996年1月1日至2020年1月15日。
- 纳入8项研究代表9个人群,包括1452名HIV感染女性,随访6至33个月。
- 使用随机效应荟萃分析,通过I2统计量检验异质性,PROSPERO注册号CRD42018115631。
关键数值与推荐
- ART使用者较未使用者CIN2+检出cOR=0.70(95%CI:0.36-1.36)。
临床怎么用
- 对HIV感染女性推荐早期启动ART以降低CIN2+风险。
- 将CIN2+筛查和管理整合入HIV常规关怀。
- 关注HIV病毒载量和CD4+计数作为CIN2+风险分层参考。
局限性
- 纳入研究数量较少(8项),部分分析异质性较高(I2最高达81.3%)。
- ART与CIN2+关联的证据强度较弱,调整后置信区间宽。
- 中低收入国家未观察到显著关联,可能受限于研究数量和数据质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the association of antiretroviral therapy (ART), CD4+ count and human immunodeficiency virus (HIV) plasma viral load (PVL) on high-grade cervical intraepithelial neoplasia (CIN2+) detection at follow-up after CIN management among women living with HIV (WLHIV). METHODS: Medline, Embase, Global Health, and PubMed were searched from 1 January 1996 to 15 January 2020. Eligible studies investigated the association of ART, CD4+ count, or HIV PVL on histology-confirmed CIN2+ detection at follow-up. Summary estimates were obtained using random-effects meta-analyses; heterogeneity was examined using I2 statistic. PROSPERO registration: CRD42018115631. RESULTS: Eight studies representing 9 populations were identified, including 1452 WLHIV followed between 6 and 33 months post-CIN management. Pooled data from 8 populations (n = 1408) suggested weak evidence of a decreased risk of CIN2+ detection at follow-up among ART users compared to ART-naive women (crude odds ratio [cOR] = 0.70, 95% confidence interval [CI]: .36-1.36; I2 = 64.5%, P = .006; adjusted risk ratio [aRR] from 3 studies = 0.66, 95% CI: .20-2.24; I2 = 78.7%, P = .009). A significant association was observed in high-income countries (cOR = 0.24, 95% CI: .13-.45; I2 = 0.0%, P = .77) but not in low and middle-income countries (cOR = 1.13, 95% CI: .67-1.92; I2 = 18.8%, P = .30).In 3 populations, ART users with HIV PVL <50 copies/ml were less likely to have CIN2+ detection at follow-up (vs ≥50 copies/mL: cOR = 0.55, 95% CI: .32-.94; I2 = 0.0%, P = .23).There was weak evidence of decreased CIN2+ detection at follow-up among WLHIV with higher contemporary CD4+ cell counts (≥200 cells/µL vs <200 cells/µL [cOR = 0.36, 95% CI: .04-3.13; I2 = 81.3%, P = .021]) and significant evidence among women with a higher nadir CD4+ count (≥350 cells/µl vs <200 cells/µl [adjusted hazard ratio [aHR] = 0.35, 95% CI: .15-.84; I2 = 0%, P = .64]). CONCLUSION: ART may reduce the risk of CIN2+ detection at follow-up; this effect is most likely enhanced by a combination of adequate HIV control and excisional CIN treatment. Our findings support recommendations of early ART and the integration of CIN2+ screening and management into HIV care.
引用
- Atemnkeng N, Aji AD, de Sanjose S, et al. Antiretroviral Therapy and Detection of High-grade Cervical Intraepithelial Neoplasia (CIN2+) at Post-CIN Management Follow-up Among Women Living With Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2020. PMID: 32162657. doi:10.1093/cid/ciaa238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。